COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE

被引：0

作者：

Silva, C. ^{[1
]}

Esparteiro, J. ^{[1
]}

Fonseca, A. ^{[1
]}

Laires, P. A. ^{[1
]}

机构：

[1] Novartis Farma, Porto Salvo, Portugal

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.09.1762

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS48

引用

页码：S296 / S296

页数：1

共 50 条

[1] COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE
Silva, C.
Esparteiro, J.
Fonseca, A.
Laires, P. A.
VALUE IN HEALTH, 2018, 21 : S295 - S295
[2] SECUKINUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIASIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Esparteiro, J.
Silva, C.
Laires, P. A.
VALUE IN HEALTH, 2018, 21 : S427 - S427
[3] SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Laires, P. A.
Silva, C.
Esparteiro, J.
VALUE IN HEALTH, 2018, 21 : S428 - S428
[4] SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Laires, P. A.
Esparteiro, J.
Fonseca, A.
Silva, C.
VALUE IN HEALTH, 2018, 21 : S294 - S295
[5] SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE
Seyhun, O.
Dinc, M.
Sevgi, S.
Aksun, F.
Basegmez, O.
Kus, M.
VALUE IN HEALTH, 2019, 22 : S699 - S699
[6] SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS: A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.
Yahiaoui, S.
Ramakrishna, G.
Toumi, J.
Burke, J.
Kooli, A.
VALUE IN HEALTH, 2018, 21 : S292 - S292
[7] SECUKINUMAB VERSUS INFLIXIMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS: A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.
Yahiaoui, S.
Ramakrishna, G. S.
Toumi, J.
Burke, J.
Kooli, A.
VALUE IN HEALTH, 2018, 21 : S292 - S292
[8] Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
Gisondi, Paolo
Geat, Davide
Maurelli, Martina
Degli Esposti, Luca
Bellinato, Francesco
Girolomoni, Giampiero
VACCINES, 2022, 10 (05)
[9] Secukinumab vs Adalimumab for the Treatment of Psoriatic Arthritis: A Cost per Responder Analysis at 48 Weeks from a Canadian Perspective
Gladman, Dafna
Nikoglou, Efthalia
Gunda, Praveen
Chiva-Razavi, Sima
Jugl, Steffen
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 924 - 924
[10] COST PER RESPONDER OF APREMILAST VERSUS ETANERCEPT AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Tencer, T.
Clancy, Z.
Zhang, F.
VALUE IN HEALTH, 2014, 17 (07) : A376 - A376

← 1 2 3 4 5 →